IN BRIEF: EMV Capital "optimistic" after annual AuM and revenue growth

EMV Capital PLC - life sciences-focused investor - Reports results for 2025. Assets under management totals GBP112.5 million as at December 31, up from GBP98.5 million one year prior. Group revenue increases 17% to GBP2.9 million from GBP2.5 million the year before, "driven by higher corporate finance fees, increased fundraising activity and higher recurring fund management fees following the full operational integration of Martlet Capital." Core revenue increases 31% to GBP3.2 million from GBP2.4 million. Pretax loss narrows to GBP685,000 from GBP3.7 million. EMV says syndicated fundraising during the period totalled GBP12.0 million across 14 portfolio companies, up from GBP10.6 million across 12 companies.

Looking ahead, Chief Executive Officer Ilian Iliev comments: "The accelerating demands of AI infrastructure, energy efficiency, healthcare innovation and industrial resilience continue to reinforce the relevance of our portfolio. Several portfolio companies are approaching important commercial, technical and regulatory milestones, and we believe the group is well positioned to benefit as market conditions improve. While we remain disciplined and cautious, we are increasingly optimistic about the medium-term opportunity set across both our existing portfolio and new investment pipeline."

Current stock price: 46.00 pence, down 4.2% in London on Tuesday

12-month change: up 14%

By Emma Curzon, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2026 Alliance News Ltd. All Rights Reserved.

Emv Capital